Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have earned a consensus rating of “Hold” from the seventeen ratings firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $44.5385.

Several equities analysts recently commented on HIMS shares. Leerink Partners upgraded Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, December 4th. Barclays began coverage on Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target for the company. Evercore ISI initiated coverage on shares of Hims & Hers Health in a research report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price objective on the stock. Zacks Research downgraded shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Finally, Bank of America boosted their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research note on Tuesday, November 4th.

Insider Buying and Selling

In related news, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the transaction, the insider owned 6,175 shares of the company’s stock, valued at $226,684.25. This represents a 53.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the transaction, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 134,611 shares of company stock valued at $4,895,914 in the last three months. 13.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Farallon Capital Management LLC lifted its holdings in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Hims & Hers Health by 502.2% during the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after purchasing an additional 2,128,587 shares during the last quarter. Clear Street LLC purchased a new position in Hims & Hers Health in the 2nd quarter worth $83,582,000. Norges Bank bought a new stake in Hims & Hers Health in the second quarter worth $78,464,000. Finally, Clear Street Group Inc. bought a new stake in Hims & Hers Health in the third quarter worth $87,372,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $29.63 on Tuesday. Hims & Hers Health has a 1 year low of $23.97 and a 1 year high of $72.98. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The stock has a market capitalization of $6.74 billion, a PE ratio of 54.86, a P/E/G ratio of 5.02 and a beta of 2.37. The company’s 50 day simple moving average is $34.95 and its two-hundred day simple moving average is $45.05.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 earnings per share. Analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has initiated a share repurchase program on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.